- Corporate Information
- SEC FIlings
- Company News
- New Facility
NanoViricides Inc.
1 Controls Drive,
Shelton, CT 06484
Ph No:- 203-937-6137
Fax No:- 203-859-5095
Email:- info@nanoviricides.com
February 15, 2024 - NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
January 4, 2024 - NanoViricides to Present at the Biotech Showcase in San Fransisco
November 28, 2023 - The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
November 15, 2023 - NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
November 14, 2023 - Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
October 11, 2023 - NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
August 21, 2023 - The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
July 11, 2023 - Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model
May 31, 2023 - NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET
May 16, 2023 - NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin
April 25, 2023 - NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient
April 17, 2023 - NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate
April 5, 2023 - NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates
February 15, 2023 - NanoViricides Has Filed its Quarterly Report - Company has Begun Production of Coronavirus Drug for Clinical Trials
January 4, 2023 - NanoViricides, Inc. to Present at the Biotech Showcase(TM) 2023 Conference in San Fransisco on January 9th at 10:30am PT
December 6, 2022 - NanoViricides, Inc. to Present at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 2:00pm ET
November 15, 2022 - NanoViricides, Inc. Has Filed its Quarterly Report- Coronavirus Drug NV-CoV-2 IND Stage
October 14, 2022 - NanoViricides, Inc. Has Filed its Annual Report- Coronavirus Drug NV-CoV-2 IND Stage
August 9, 2022 - NanoViricides Provides Additional Details on Its Rapid Monkeypox Drug Strategy
August 4, 2022 - NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus
May 16, 2022 - NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis
April 15, 2022 - NanoViricides Provides Update On NV-CoV-2 Coronavirus Drug Candidate Program
February 15, 2022 - NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready
November 16, 2021 - NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials
November 15, 2021 - NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2
October 13, 2021 - NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage
October 11, 2021 - NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity
October 4, 2021 - NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference
September 27, 2021 - NanoViricides, Inc. Invites You to Join Us at the Benzinga Healthcare Small Cap Conference for Update on Pan-Coronavirus COVID-19 Drug Development Program
September 14, 2021 - NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID- 19 Drug Development
February 17, 2021 - NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2020 - Has Sufficient Cash, Coronavirus Drug Candidate Safe in GLP Safety Toxicology Moving Towards IND
February 8, 2021 - NanoViricides's Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP and non-GLP Animal Safety Studies
January 27, 2021 - Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants, Says NanoViricides, Inc.'s President, Dr. Anil Diwan
November 19, 2020 - NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA
November 17, 2020 - NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2020 - Has Sufficient Cash, Coronavirus Drug Development Progress
November 11, 2020 - NanoViricides Has Engaged Calvert Labs for Safety Pharmacology Studies of Its Drug for the Treatment of COVID-19
October 15, 2020 - NanoViricides, Inc. Has Filed its Annual Report: Strengthened Financial Position and Rapidly Developing Novel Coronavirus Drug Program
September 16, 2020 - NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19
September 2, 2020 - NanoViricides to Present COVID-19 Drug Update at The LD 500 Virtual Conference
July 13, 2020 - NANOVIRICIDES CLOSES ON $11.5 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK
June 30, 2020 - NanoViricides Announces Addition to Russell Microcap(R) Index
June 9, 2020 - NanoViricides Signs Memorandum of Understanding for Human Coronavirus Drug Development License
May 21, 2020 - NanoViricides Announces Pricing of $10.2 Million Registered Direct Offering
May 20, 2020 - Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus
May 18, 2020 - Honorable Ex-Congressman Todd Rokita Joins the Board of Directors of NanoViricides, Inc
May 12, 2020 - NanoViricides Develops Highly Effective Broad-Spectrum Drug Candidates Against Coronaviruses
April 6, 2020 - U.S. Senator Richard Blumenthal Visited NanoViricides Inc. for Update on Coronavirus Drug Development Efforts
March 16, 2020 - Coronavirus Drug Development Update from NanoViricides, Inc.
February 24, 2020 - NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2019 - Has Sufficient Cash, HerpeCide™ Drug Candidate IND Application Development in Progress
February 12, 2020 - Dr. Mak Jawadekar Joins the Board of Directors of NanoViricides, Inc.
February 10, 2020 - NANOVIRICIDES PRESIDENT Dr. DIWAN WAS INTERVIEWED BY THE VARNEY SHOW ON FOX BUSINESS NEWS
February 4, 2020 - Nanoviricides President Dr. Diwan Was Interviewed By The Kennedy Show On Fox Business News
January 30, 2020 - NanoViricides Confirms It Has Been Working On A Treatment For The Novel Wuhan Coronavirus
January 24, 2020 - NANOVIRICIDES CLOSES ON $8.625 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK
January 21, 2020 - NANOVIRICIDES PRICES $7.5 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK
January 9, 2020 - NanoViricides Successfully Completes Required Genetic Toxicology Testing of Lead Drug Candidate NV-HHV-101
January 7, 2020 - NanoViricides Has Initiated Genetic Toxicology Testing Required for an IND for Its Drug Candidate
January 6, 2020 - NanoViricides Receives Cash Infusion of $2.25 Million
December 9, 2019 - NanoViricides President Dr. Anil Diwan Provides Responses to Shareholder Questions at the Annual Meeting of Shareholders
December 6, 2019 - NanoViricides Annual Meeting of Shareholders to be Held on Saturday, December 7th, 2019 at the Sheraton Hotel, Stamford, CT
December 3, 2019 - NanoViricides Founder Dr. Diwan Provides $2,000,000 Loan Commitment to the Company
December 2, 2019 - NanoViricides Has Initiated Required Safety Pharmacology Assessment of Lead Drug Candidate towards IND
November 18, 2019 - NanoViricides Files Quarterly Report for Period Ending September 30, 2019 - HerpeCide™ Drug Candidate IND Enabling Studies Update, Progressing Towards Clinical Trials
November 4, 2019 - NanoViricides Completes Licensing for VZV Field which Includes Shingles Drug Development
October 31, 2019 - NanoViricides Initiates Required Dermal Sensitization and Ocular Irritation Testing of Lead Drug Candidate towards IND
October 9, 2019 - NanoViricides Has Initiated Bio-analytical Studies as Part of IND-Enabling Safety and Toxicology Studies of Lead Candidate NV-HHV-101
October 3, 2019 - NanoViricides is Creating Nanomedicines to Develop Antiviral Therapies to Combat Shingles and Herpes Viruses
September 30, 2019 - NanoViricides, Inc. Files Form S-1 Registration Statement
September 12, 2019 - NanoViricides, Inc. Announces One-for-Twenty Reverse Stock Split
August 26, 2019 - NanoViricides, Inc. Has Filed its Annual Report, Company Advancing Rapidly Towards First IND
August 5, 2019 - NanoViricides Reports Its First Drug Candidate is on Track with GLP Safety/Toxicology Studies toward Human Clinical Trials
June 10, 2019 - NanoViricides, Inc. Appoints Dr. Mark Day to its Board of Directors
June 3, 2019 - NanoViricides has Received Favorable FDA Comments on Its Pre-IND Application for the Lead Drug Candidate
May 13, 2019 - NanoViricides Announces Completion of Production of its Lead Candidate for Upcoming GLP Tox Package Studies
April 16, 2019 - NanoViricides Submits Pre-IND Briefing Documents to the US FDA
March 26, 2019 - NanoViricides has Requested a Pre-IND Meeting with the US FDA
March 12, 2019 - NanoViricides Reports Successful Completion of Another Important Safety Study towards an IND
March 5, 2019 - NanoViricides Reports Excellent Safety Profile of Its First Drug Candidate in Dermal Treatment Study
February 27, 2019 - NanoViricides Announces $2.5 Million Financing in a Registered Direct Offering
February 26, 2019 - NanoViricides Reaches an Agreement on Terms of License for Shingles Virus Drug Development
February 19, 2019 - NanoViricides Files Quarterly Report for Period Ending December 31, 2018 - HerpeCide Drug Candidate Progressing in IND-Enabling Studies Towards Clinical Trials
February 11, 2019 - NanoViricides President Dr. Diwan to Present at the BIO CEO & Investor 2019 Event in New York City Tomorrow Feb 12th at 2-30pm
February 4, 2019 - NanoViricides Has Initiated IND-Enabling Safety/Toxicology Studies for Its First Drug Candidate Moving towards Human Clinical Trials
January 7, 2019 - NANOVIRICIDES, INC. CEO DR. TARAPOREWALA TO PRESENT AT THE BIOTECH SHOWCASETM INVESTMENT CONFERENCE IN SAN FRANCISCO ON JANUARY 7, 2019
November 26, 2018 - NanoViricides Files Quarterly Report for Period Ending September 30, 2018
October 29, 2018 - NanoViricides, Inc. Appoints Mr. James Sapirstein to its Board of Directors
October 22, 2018 - NanoViricides CEO Dr. Irach Taraporewala Presents a Letter to Shareholders
October 15, 2018 - NanoViricides Has Filed its Annual Report, Company Reports Strong Progress in Advancement of HerpeCide Program
September 28, 2018 - NanoViricides Inc. to Present at the MicroCap Conference in New York City on October 1
September 5, 2018 - Nanoviricides Inc. to Present at 20th Annual Rodman & Renshaw Conference in NYC on Sept 6th
August 7, 2018 - Nanoviricides Reports Its Topical Dermal Shingles Candidates Effective in Reducing Pain in Animal Study
July 23, 2018 - NanoViricides Inc. Welcomes Dr. Irach Taraporewala as the New CEO
July 12, 2018 - NanoViricides Provides Update on Recent Events
June 26, 2018 - Progress of NanoViricides' Shingles Drug Program Presented at the 31st International Conference on Antiviral Research
May 14, 2018 - NanoViricides Provides Update, Says Company is Stable and is Moving Steadily towards Clinical Trials
December 6, 2017 - Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates
October 26, 2017 - Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Center
September 29, 2017 - NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials
September 11, 2017 - NANOVIRICIDES, INC. ANNOUNCES ITS CEO Dr. SEYMOUR TO PRESENT AT THE 19TH ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE IN NEW YORK CITY ON SEPTEMBER 12, 2017
July 10, 2017 - NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin
June 20, 2017 - NanoViricides' Abstract Accepted for Poster Presentation at the 2017 Annual Meeting of American Society of Virology
June 13, 2017 - NanoViricides CEO to Present Information on Its Topical Shingles Treatment At the 2017 Marcum Investor Conference in New York City
May 16, 2017 - NanoViricides Files Quarterly Report for Period Ending 2017-03-31
February 16, 2017 - NanoViricides Files Quarterly Report for Period Ending 2016-12-31
February 13, 2017 - NanoViricides Reports the Company's Director Dr. Boniuk Converted Series B Debenture to Equity Effectively Raising $5M in New Equity for the Company
December 1, 2016 - NanoViricides Publishes a Letter from the CEO to Shareholders on its Website
November 15, 2016 - NanoViricides Files Quarterly Report for Period Ending 2016-09-30
November 7, 2016 - NanoViricides President Dr. Diwan Gave Invited Talks on Regulatory Aspects of Nanomedicines
October 31, 2016 - NanoViricides Signs Agreement with SUNY Upstate Medical Center for Testing of Its Drug Candidates for the Treatment of Shingles
October 11, 2016 - NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials
August 25, 2016 - NanoViricides Reports on Senator Murphy's Visit to the Company's Shelton Campus
June 20, 2016 - NanoViricides Reports On Progress of Its Drug Candidates against Herpesviruses
June 9, 2016 - NanoViricides to Present at the LDMicro Invitational Conference
June 7, 2016 - NanoViricides to Present at the BIO2016 International Convention - on June 8, 2016, at 11a.m. Pacific Time
May 31, 2016 - NanoViricides Signs Agreement with St. Jude Children's Research Hospital for further Influenza Drug Development
May 11, 2016 - NanoViricides Files Quarterly Report for Period Ending 2016-03-31
March 21, 2016 - NanoViricides, Inc. CEO Dr. Seymour Interview by Small Cap Nation is on YouTube
February 22, 2016 - NanoViricides' Anti-Virus Technology Published in Handbook of Clinical Nanomedicine
February 16, 2016 - NanoViricides Signs Agreement for Ocular Testing of Its Drug Candidates for the Treatment of Herpes Keratitis with the Baylor College of Medicine
February 11, 2016 - NanoViricides Signs Agreement for Ocular Testing of Its Drug Candidates for the Treatment of Herpes Keratitis with the University of Pittsburgh
February 10, 2016 - NanoViricides Files Quarterly Report for Period Ending 2015-12-31
February 1, 2016 - NanoViricides Signs Agreement with the University of Wisconsin for Testing of Anti-Viral Candidates
January 25, 2016 - NanoViricides 2015 Annual Shareholders Meeting Was Held on January 23, 2016 - Company Discussed Accomplishments and Future Strategy
January 12, 2016 - NanoViricides CEO Dr. Eugene Seymour to Present at the Biotech Showcase in San Fransisco on Wednesday
November 10, 2015 - NanoViricides Files Quarterly Report for Period Ending 2015-09-30
September 16, 2015 - NanoViricides Files Annual Report
August 17, 2015 - NanoViricides Accelerates its Herpes Drug Development Program
August 10, 2015 - NanoViricides Reports that the Dramatic Effects of Its Topical Anti-Herpes Treatment were Reproduced Once Again in an Animal Model in a Different Laboratory
May 18, 2015 - NanoViricides Files Quarterly Report for Period Ending 2015-03-31
April 27, 2015 - NanoViricides Discusses the Strong Effectiveness of Its Anti-Herpes Drug Candidates in a Lethal Animal Model of Dermal Herpes Infection
April 20, 2015 - NanoViricides Reports that Its Topical Anti-Herpes Treatment Dramatically Improves Clinical Symptoms in an Animal Model
April 6, 2015 - NanoViricides Provides an Update on Its Progress over the Last Quarter
March 9, 2015 - NanoViricides Issued Registered Shares as Interest to Certain Debenture Holders
February 25, 2015 - NanoViricides Files Quarterly Report for Period Ending 2014-12-31
February 17, 2015 - NanoViricides Announces that a Research Report on the Company has been Published By Midtown Partners, Inc., a New York Investment Bank
January 22, 2015 - Nanoviricides Reports that the FluCide® Candidate was found to be Very Safe in cGLP-like Safety and Toxicology Study in Rats Performed by BASi
January 21, 2015 - NanoViricides, Inc.'s Executive Officers Report Insider Purchases of Common Stock
January 7, 2015 - NanoViricides, Inc. Completes Purchase of cGMP-compliant Pilot Production Facility
November 20, 2014 - NanoViricides Says Injectable FluCide™ Selected In Top Ten Project to Watch - Presentation Today At the Therapeutics Area Partnerships Meeting in Boston
November 18, 2014 - NanoViricides CEO, Eugene Seymour, MD, MPH, Invited to Discuss the Current Ebola Outbreak on Fox Business News at 9PM EDT Tonight
November 17, 2014 - NanoViricides, Inc. Files Quarterly Report - Reports Further Improved Strong Cash Position Sufficient for Clinical Trials of its First Two Drug Candidates
October 27, 2014 - NanoViricides, Inc. Signs CRADA for Material Transfer with USAMRIID for Evaluating Its Anti-Ebola Drug Candidates
October 7, 2014 - NanoViricides CEO, Eugene Seymour, MD, MPH, Invited to Discuss the Current Ebola Outbreak on Fox Business News at 9PM EDT Tonight
October 1, 2014 - NanoViricides Reports FluCide™ Samples Were Shipped To BASi For Start of Safety/Toxicology Studies; Also Reports That Ebola Drug Candidates are Being Synthesized
September 30, 2014 - NanoViricides Files Annual Report
September 16, 2014 - NanoViricides Reports That Its CEO Dr. Seymour Will Be Interviewed about the Evolving Ebola Crisis on Fox Business News at 9PM EDT This Evening
September 9, 2014 - NanoViricides Reports That It Has Designed and Commenced Synthesis of Novel Ebola Drug Candidates; Dr. Seymour To Present At The Rodman And Renshaw Conference In New York Today
September 8, 2014 - NanoViricides Raises Approximately $7.5 Million Upon Exercise of Certain Old Warrants by Its Long Standing Investors
August 12, 2014 - NanoViricides to Ring Opening Bell at New York Stock Exchange
August 4, 2014 - NanoViricides to Restart its Anti-Ebola Virus Drug Development Program
July 23, 2014 - NanoViricides President Dr. Diwan was an Invited Participant at the Prestigious CEO Roundtable
July 14, 2014 - NanoViricides President Dr. Diwan Presented FluCide Data at the 3rd Annual Influenza Conference held by GTC Bio on Friday, July 11
July 2nd, 2014 - NanoViricides Reports that its Director Dr. Milton Boniuk, a Director, Has Invested $5M into the Company in a Convertible Debenture
June 25th, 2014 - NanoViricides Reports that a Certificate of Occupancy has been Issued for the New cGMP Manufacturing and R&D Facility in Shelton, CT
June 19th, 2014 - NanoViricides President Dr. Diwan to Present at the Wall Street Analyst Forum Today, June 19th, in New York City
June 4th, 2014 - NanoViricides CEO Dr. Seymour to Present at the LD Micro Invitational Conference Today, June 4th
May 19th, 2014 - NanoViricides, Inc. Files Quarterly Report - Reports a Strong Cash Position Sufficient for Clinical Trials of its First Two Drug Candidates
May 5th, 2014 - NanoViricides Reports Novel Drug Candidates for Treatment of the MERS (Middle East Respiratory Syndrome) Corona Virus Ready For Animal Testing
April 16th, 2014 - NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector
March 31st, 2014 - NanoViricides, Inc. President Dr. Anil R. Diwan Recognized as Researcher of the Year by BusinessNewHaven, a Connecticut Area Business Journal
March 24th, 2014 - NanoViricides Announces Patent Awards in Australia
March 12th, 2014 - NanoViricides, Inc. Has Posted Dr. Seymour's CEO Letter on the Company Website - Dr. Seymour to Present today at the Roth Capital Conference
March 7th, 2014 - NanoViricides Inc. Denies Rumor That It Is Being Acquired For $4.5B
March 5th, 2014 - NanoViricides, Inc. Announces It Has Commenced Action Against Seeking Alpha to Obtain Identity of the Anonymous Short Seller
February 26th, 2014 - NanoViricides, Inc. Reports its President & Chairman Dr. Diwan Purchased its Common Stock in the Open Market
February 20th, 2014 - NanoViricides Reports that it is Evaluating Purchase of the New Facility and cGMP Pilot Production Plant instead of a Lease
February 18th, 2014 - NanoViricides, Inc. Files Quarterly Report - Reports a Strong Cash Position Sufficient for Clinical Trials of its First Two Drug Candidates
February 14th, 2014 - NanoViricides, Inc. Demands Retraction of the Baseless and Inaccurate Libelous Article by an Anonymous Short Seller Posted on SeekingAlpha Website
February 11th, 2014 - NanoViricides CEO Dr. Seymour to be Interviewed on Radio by Yorba Media at 2PM Eastern
February 11th, 2014 - NanoViricides, Inc. Responds to Baseless Seeking Alpha Article
February 4th, 2014 - NanoViricides Signs Agreement with Viroclinics Biosciences BV for Testing of Various NanoViricides Against Specific Viruses of Current Concern
January 27th, 2014 - NanoViricides Reports Construction of its New Facility and cGMP Pilot Production Plant is Nearing Completion, also Provides Details of its $20 Million Registered Direct Offering
January 21st, 2014 - NanoViricides Announces that It Has Raised $20 Million in a Registered Direct Offering
December 11th, 2013 - NanoViricides Announces that its Annual Meeting was held on December 9th, 2013; the CEO Presentation is available on the Redesigned Website
December 2nd, 2013 - NanoViricides, Inc. Reports Excellent Safety Profile of Its Broad-Spectrum anti-Influenza Drug Candidate, FluCide™ , in a Non-GLP Study
November 21st, 2013 - Dengue Fever Case in New York Highlights Importance of NanoViricides DengueCide® Development Program
November 18th, 2013 - NanoViricides, Inc. Files Quarterly Report - Reports a Strong Cash Position Sufficient for Clinical Trials of its First Drug Candidate
November 11th, 2013 - NanoViricides Announces that DengueCide™ Has Received Orphan Drug Designation From the European Medicines Agency (EMA)
November 4th, 2013 - NanoViricides Announces Renewal of DengueCide™ Evaluation Contract with the Professor Eva Harris Laboratory at the University of California, Berkeley
October 21st, 2013 - Nanoviricides says early results indicate that FluCide® was extremely safe in a non-GLP small animal tox study
October 7th, 2013 - Nanoviricides Announces Initiation of Toxicology Study of FluCide®.
October 2nd, 2013 - Nanoviricides, Inc Announces That Its CEO, Eugene Seymour, MD, MPH will Present at LD MICRO Invitational on October 2nd in West Los Angeles
October 1st, 2013 - NanoViricides Files Annual Report - Reports Having Sufficient Funds to Advance A Drug Candidate into Clinical Trials
September 25th, 2013 - NanoViricides Begins Trading on NYSE MKT National Exchange; CEO Dr Seymour Invited to Speak at Duke University's Fuqua Business School
September 23rd, 2013 - NanoViricides to List Common Stock on New York Stock Exchange MKT; Company Stock Symbol Will Remain NNVC
September 17th, 2013 - NanoViricides Reports that its Director, Milton Boniuk, MD, has invested a Total of $7M in the Company this year
September 16th, 2013 - NanoViricides Reports It Has Successfully Improved HIVCide Drug Candidate in Cell Culture Studies
September 12th, 2013 - NanoViricides Announces that It Has Raised approximately $10.33 Million in the Registered Direct Offering Announced Recently and Discusses Shareholder Issues since the Reverse Split
September 3rd, 2013 - NanoViricides Reports that the DengueCide™ Orphan Drug Application Has Been Submitted and Received by the European Medicines Agency
August 19th, 2013 - NanoViricides Reports on Construction Progress of its New Facility and cGMP Pilot Production Plant
August 7th, 2013 - NanoViricides Announces that DengueCide™ Has Received Orphan Drug Designation From the US FDA
July 19th, 2013 - NanoViricides Reports That its CEO was Interviewed on the RedChip Money Report Program on Fox Business News TV Channel Yesterday Evening
July 8th, 2013 - NanoViricides Signs Agreement with Public Health England for Testing of Various NanoViricides Against Specific Viruses of Current Concern
July 1st, 2013 - NanoViricides Submits DengueCide™ Orphan Drug Designation Letter of Intent to File with the European Medicines Agency
June 27th, 2013 - NanoViricides to Present at the OneMedForum-NY 2013 in New York today
June 24th, 2013 - NanoViricides Appoints Chancellor of Penn State University, Professor Mukund S Kulkarni as an Independent Board Member
June 10th, 2013 - NanoViricides Submits DengueCide™ Orphan Drug Designation Application to the US FDA for dengue and dengue hemorrhagic fever
May 28th, 2013 - NanoViricides Appoints Baylor Professor Dr. Milton Boniuk as an Independent Board Member
May 21st, 2013 - NanoViricides, Inc. Files Quarterly Report - Reports a Strong Cash Position Sufficient for Initial Clinical Trials of its First Drug Candidate
May 13th, 2013 - NanoViricides, Inc. Brings in Experienced Executive as Interim CFO
April 24th, 2013 - NanoViricides to Present at the 2013 BIO International Convention in Chicago today
April 22nd, 2013 - NanoViricides Anticipates FluCide™ Drug Candidates to be Effective Against H7N9
March 20th, 2013 - NanoViricides President Dr. Diwan Invited to Present a Seminar at the Center for Biological Physics and the California NanoSystems Institute at UCLA
March 5th, 2013 - NanoViricides to Lead Sessions at the Symposium on Nanomedicines- Roadmap to Commercialization in Rockville, MD tomorrow
February 27th, 2013 - NanoViricides announces Retirement of its Series C Convertible Preferred Stock Held by Seaside 88, LP - Company reports having more than two years of cash on hand
February 25th, 2013 - NanoViricides, Inc. Announces that Renovation for its cGMP Clinical Drug Facility has Begun; also Addresses Shareholder Concern - Knows No Reason for the Price Drop Yesterday
February 19th, 2013 - NanoViricides, Inc. Files Quarterly Report - Reports a Strong Cash Position Sufficient for Phase I Clinical Trials of its First Drug Candidate
February 11th, 2013 - NanoViricides to Present at the 15th Annual BIO-CEO Conference in NYC tomorrow
February 4th, 2013 - NanoViricides Raises $6M from Equity Investors - Reports Having Sufficient Funds for the Initial Human Clinical Trials of its Broad-spectrum anti-Influenza Drug
January 14th, 2013 - NanoViricides, Inc. Retains AES Clean Technology, Inc. for Design, Engineering and Construction of the Cleanroom Suite in its previously announced cGMP Production and Laboratory Facility
January 2nd, 2013 - NanoViricides, Inc. Appoints Id3A, LLC as Architect for its previously announced cGMP Production and Laboratory Facility
December 24th, 2012 - NanoViricides announces Completion of Previously Reported $5 Million in Shelf Offering - Company reports having more than two years of cash on hand
December 10th, 2012 - NanoViricides Appoints Project Manager and Engineering Firm for FDA cGMP Plant; Provides Update on anti-Influenza Program
November 20th, 2012 - NanoViricides Files Quarterly Report - Reports Having Sufficient Funds and Satisfactory Progress in its Advancing Pipeline
November 13th, 2012 - NanoViricides Signs Agreement with BASi for Toxicology and Safety Studies
October 16th, 2012 - NanoViricides Files Annual Report - Reports Having Sufficient Funds for Current Goals and For Advancing Its Robust Drug Pipeline
September 10th, 2012 - NanoViricides Reports Its Oral FluCide® Anti-Influenza Drug Candidates Are Superior to Oral Oseltamivir (TamiFlu®) in H1N1 Influenza Lethal Infection Model
September 4th, 2012 - NanoViricides Reports that Oral Administration of FluCide® Anti-Influenza Drug Candidates Led to Strong Antiviral Antibody Response in a Highly Lethal Animal Model
August 13th, 2012 - NanoViricides Reports That Oral Administration of FluCide®, its Anti-Influenza Drug Candidate Was Effective In Animal Model
June 29th, 2012 - NanoViricides Raises $5 Million in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand
June 25th, 2012 - NanoViricides Appoints an Independent Board Director and Chairman of the Audit Committee
May 21st, 2012 - NanoViricides Files Quarterly Report
May 14th, 2012 - NanoViricides Appoints Mr. Andrew Hahn as Consultant for Design and Construction of Pilot cGMP Production Facility
May 7th, 2012 - NanoViricides Announces Issuance of a Fundamental Patent in the USA
May 1st, 2012 - NanoViricides to Present at the 21st Annual NYBA Meeting in NYC on May 2nd
April 2nd, 2012 - NanoViricides Announces Successful Pre-IND Meeting with the US FDA
March 5th, 2012 - NanoViricides Announces US FDA Has Confirmed Pre-IND Meeting Date
February 13th, 2012 - NanoViricides to Present at the 14th Annual BIO-CEO Conference in NYC today
December 5th, 2011 - NanoViricides, Inc Announces That It Has Submitted a Pre-IND Meeting Request to the US FDA For Its Anti-Influenza Clinical Drug Candidate, FluCide™
November 15th, 2011 - NanoViricides Files Quarterly Report
November 3rd, 2011 - NanoViricides Raises an Additional $5 Million in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand
October 24th, 2011 - NanoViricides' Anti-Virus Technology Published in Bionanotechnology II: Global Prospects
October 17th, 2011 - NanoViricides Files Annual Report - Reports Having Sufficient Funds for Current Goals
October 4th, 2011 - NanoViricides Inc to Present at the Partnership Opportunities in Drug Delivery (PODD) Conference in Boston Today
September 26th, 2011 - NanoViricides Inc to Present at the 10th Annual NanoBusiness Conference
September 21st, 2011 - NanoViricides Inc. to Present at the French Biotech Tour - Infectious Diseases Meeting
September 19th, 2011 - NanoViricides Announces Acquisition of New Space for Future Pilot cGMP Production
September 6th, 2011 - NanoViricides Selects Its First FluCide™ Clinical Candidate For FDA Submission
June 16th, 2011 - NanoViricides Announces That Its CEO Will Present Information about the Company at an Investor Meeting June 16th in Denver
August 15th, 2011 - NanoViricides Reports Sustained Anti-HIV Effect with Much Shorter Drug Dosing than HAART Drug Cocktail
June 6th, 2011 - NanoViricides to Present Influenza Study Results at the TechConnect World 2011 Conference in Boston
August 8th, 2011 - NanoViricides Reports That It is Financially Sound and is Progressing Towards Initial FDA Submission
May 23rd, 2011 - NanoViricides Files Quarterly Report
August 1st, 2011 - NanoViricides Expands On Prior HIVCide Effectiveness Release
July 27th, 2011 - NanoViricides Raises $2.5M in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand
April 20th, 2011 - NanoViricides Raises an Additional $5 Million in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand
July 25th, 2011 - NanoViricides Reports Anti-HIV Efficacy Equivalent to HAART Drug Cocktail Treatment in Animal Study, Successfully Advancing its HIVCide Lead Optimization Program
July 5th, 2011 - NanoViricides Signs Consulting Agreement with BCG for FDA Submission
April 4th, 2011 - NanoViricides Reports FluCide™ Drug Candidates Found to Offer Significant Protection Against Devastating Lung Lesions in Lethal Influenza Infection Animal Study
June 22nd, 2011 - NanoViricides, Inc., to Present at OneMedForum NY 2011 Trans-Atlantic Conference for Emerging Healthcare and Life Science Companies
March 21st, 2011 - NanoViricides Reports Treatment with its FluCide Drug Candidate Achieves Dramatic Full Survival in Recent H1N1 Influenza Lethality Study
June 20th, 2011 - NanoViricides to Lease New Space for cGMP Production
February 23rd, 2011 - NanoViricides Files Quarterly Report
Tab content
Contact Information
NanoViricides, Inc.
1 Controls Drive,
Shelton, CT 06484
Phone: +1-203-937-6137
Phone: +1-888-591-3579
Fax: +1-203-859-5095
E-mail: info@nanoviricides.com